Biobanking and pharmacogenomics

Catherine A. McCarty, Russell A. Wilke

Research output: Contribution to journalComment/debate

32 Citations (Scopus)

Abstract

The study of genetic determinants underlying drug outcome is rapidly advancing. Initial success was realized within the context of candidate pharmacokinetic genes and serious adverse drug reactions, particularly for drugs with narrow therapeutic indices. Although genetic predictors of outcome have proven useful in other contexts, effect size has typically been small. To address these challenges, the clinical and scientific communities have begun studying larger numbers of gene variants (often at the genome-wide level) in cohorts of increasing sample size. Electronic health records are being increasingly used for this purpose. Longitudinal data available in practice-based datasets will position investigators to characterize genetic factors with small but reproducible effects on drug outcome in the context of gene-environment interactions.

Original languageEnglish (US)
Pages (from-to)637-641
Number of pages5
JournalPharmacogenomics
Volume11
Issue number5
DOIs
StatePublished - May 1 2010

Fingerprint

Pharmacogenetics
Pharmaceutical Preparations
Gene-Environment Interaction
Electronic Health Records
Drug-Related Side Effects and Adverse Reactions
Sample Size
Genes
Pharmacokinetics
Research Personnel
Genome
Therapeutics

Keywords

  • Biobank
  • Electronic health record
  • GWAS
  • Personalized medicine
  • Pharmacogenomics

Cite this

McCarty, C. A., & Wilke, R. A. (2010). Biobanking and pharmacogenomics. Pharmacogenomics, 11(5), 637-641. https://doi.org/10.2217/pgs.10.13

Biobanking and pharmacogenomics. / McCarty, Catherine A.; Wilke, Russell A.

In: Pharmacogenomics, Vol. 11, No. 5, 01.05.2010, p. 637-641.

Research output: Contribution to journalComment/debate

McCarty, CA & Wilke, RA 2010, 'Biobanking and pharmacogenomics', Pharmacogenomics, vol. 11, no. 5, pp. 637-641. https://doi.org/10.2217/pgs.10.13
McCarty, Catherine A. ; Wilke, Russell A. / Biobanking and pharmacogenomics. In: Pharmacogenomics. 2010 ; Vol. 11, No. 5. pp. 637-641.
@article{34a2bc5040114ff682663c3c4624f233,
title = "Biobanking and pharmacogenomics",
abstract = "The study of genetic determinants underlying drug outcome is rapidly advancing. Initial success was realized within the context of candidate pharmacokinetic genes and serious adverse drug reactions, particularly for drugs with narrow therapeutic indices. Although genetic predictors of outcome have proven useful in other contexts, effect size has typically been small. To address these challenges, the clinical and scientific communities have begun studying larger numbers of gene variants (often at the genome-wide level) in cohorts of increasing sample size. Electronic health records are being increasingly used for this purpose. Longitudinal data available in practice-based datasets will position investigators to characterize genetic factors with small but reproducible effects on drug outcome in the context of gene-environment interactions.",
keywords = "Biobank, Electronic health record, GWAS, Personalized medicine, Pharmacogenomics",
author = "McCarty, {Catherine A.} and Wilke, {Russell A.}",
year = "2010",
month = "5",
day = "1",
doi = "10.2217/pgs.10.13",
language = "English (US)",
volume = "11",
pages = "637--641",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Biobanking and pharmacogenomics

AU - McCarty, Catherine A.

AU - Wilke, Russell A.

PY - 2010/5/1

Y1 - 2010/5/1

N2 - The study of genetic determinants underlying drug outcome is rapidly advancing. Initial success was realized within the context of candidate pharmacokinetic genes and serious adverse drug reactions, particularly for drugs with narrow therapeutic indices. Although genetic predictors of outcome have proven useful in other contexts, effect size has typically been small. To address these challenges, the clinical and scientific communities have begun studying larger numbers of gene variants (often at the genome-wide level) in cohorts of increasing sample size. Electronic health records are being increasingly used for this purpose. Longitudinal data available in practice-based datasets will position investigators to characterize genetic factors with small but reproducible effects on drug outcome in the context of gene-environment interactions.

AB - The study of genetic determinants underlying drug outcome is rapidly advancing. Initial success was realized within the context of candidate pharmacokinetic genes and serious adverse drug reactions, particularly for drugs with narrow therapeutic indices. Although genetic predictors of outcome have proven useful in other contexts, effect size has typically been small. To address these challenges, the clinical and scientific communities have begun studying larger numbers of gene variants (often at the genome-wide level) in cohorts of increasing sample size. Electronic health records are being increasingly used for this purpose. Longitudinal data available in practice-based datasets will position investigators to characterize genetic factors with small but reproducible effects on drug outcome in the context of gene-environment interactions.

KW - Biobank

KW - Electronic health record

KW - GWAS

KW - Personalized medicine

KW - Pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=77951541774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951541774&partnerID=8YFLogxK

U2 - 10.2217/pgs.10.13

DO - 10.2217/pgs.10.13

M3 - Comment/debate

C2 - 20415552

AN - SCOPUS:77951541774

VL - 11

SP - 637

EP - 641

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 5

ER -